Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

SOUTHAMPTON, England, April 21 /PRNewswire/ -- Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs.

Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. Most recently an independent regulatory affairs consultant, Rachel has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Previously Rachel founded ChapelPharma a regulatory consultancy that was acquired by Hesperion in 2004.

Dr Jim Phillips, CEO of Vantia Therapeutics, said: "Rachel brings to Vantia years of experience across all regulatory aspects of the global development of new chemical entities from pre-clinical through to Phase III. She is an excellent addition to our already high-quality management team at Vantia and I look forward to working with her as our clinical and pre-clinical pipeline continues to mature."

Rachel Morten, Head of Regulatory Affairs, said: "Vantia has already made great progress with its pipeline, with the Phase IIa trial of VA106483 for nocturia recently completed and dosing complete in the Phase I trial of VA111913 for dysmenorrhoea. These products target conditions which affect millions of people and are poorly served by current treatments. It is the quality of these programmes, the pre-clinical pipeline and the drug discovery engine that made the opportunity of joining the team at Vantia so exciting."

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Its rapidly advancing clinical pipeline includes VA106483 for nocturia
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... (PRWEB) October 17, 2014 ... offers a full line of Styrene-Butadiene polymer ... barrier coatings and a variety of other ... provide outstanding performance in these applications.  , ... in performance and cost effectiveness.  SB polymer ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The North ... concerned market in North America with analysis and forecast ... in 2013, and is expected to reach $1329.6 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. This also provides ...
(Date:10/17/2014)... Mediso stellt den MultiScan ... MultiScan-Produktreihe, das speziell für Forschungsanwendungen in der klinischen ... (Large Field of view Extreme Resolution) mit einem ... Sichtfeld in Breitenrichtung von 15 cm, einer PET-Auflösung ... % soll für die vorklinische Hirnforschung eingesetzt werden. ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 /PRNewswire/ ... - Research and Markets ( http://www.researchandmarkets.com/research/6cbkgn/latest_guidebook ) ... Guidebook for Conducting Medical Device Clinical Evaluation ... to Practices (2014 Edition)"  report to their ... , China,s regulatory framework ...
Breaking Biology Technology:Mallard Creek Polymers Reminds Industry of the Full Line of Styrene-Butadiene Polymer Emulsions 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 2The North American flexible display market and is expected to reach $1329.6 million by 2018 - New Report by MicroMarket Monitor 3Mediso enthüllt neues Forschungswerkzeug MultiScan LFER 150 PET/CT 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 2Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) 3
... Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... tumor specific data to enhance the value of oncology drugs, today ... 2009. Full details of the Company,s financial results are available in ... , Total revenues for the first quarter of ...
... SINGAPORE, Sept. 14 China Agro-Technology Holdings (OTC ... website which is focused on spotlighting the company,s focus on ... website is located at www.chinaagrotech.com. , , ... Holdings Ltd., headquartered in Singapore, is focused on becoming a ...
... , , ... 14 Tobira Therapeutics Inc., a clinical stage biotechnology ... treatment of life-threatening and life-altering infectious diseases, today announced ... randomized study of TBR-652 in sixty healthy volunteers. ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results 5Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV 2
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
... proteases/caspases initiates apoptosis in mammalian cells. ... provides a simple and convenient means for ... in intact cells. The assay utilizes ... linked to rhodamine 110 (D2R), a reported ...
...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: